THE THEMATIC TIMES





Timely Trends for Today's Markets

Investing in Biotechnology: Disrupting the Healthcare Space

June 17, 2021

Biotechnology companies are some of the largest disruptors within the broader healthcare sector—these companies create new and innovative treatments for critical diseases like cancer, Alzheimer's disease, and more recently COVID-19. The <u>S-Network Medical Breakthroughs Index</u> (PMBI)—which is the underlying index for the ALPS Medical Breakthroughs ETF (SBIO)—and the <u>S-Network Healthcare Innovation Index</u> (PHIX)—which is the underlying index for the SmartTrust Healthcare Innovations Unit Investment Trust—both offer exposure to biotechnology stocks that have one or more drugs in Phase II and Phase III U.S. FDA trials. This strategy reduces the likelihood of early-stage failures in preclinical or Phase I trials, while still leaving potential for stock price growth once the drug is officially approved. See our detailed reports on PMBI <u>here</u> and PHIX <u>here</u>.

Another way biotech companies see significant stock price appreciation is through acquisitions. Since biotechnology companies focus on research & development, they are often acquired by large pharmaceutical companies which can market and distribute the treatment. In the most recent example, MorphoSys AG (MOR) recently announced the acquisition of biotechnology firm, Constellation Pharmaceuticals (CNST) at an approximately 70% premium to its previous closing price while CNST was a constituent of both PMBI and PHIX. According to DealForma, biopharma M&A activity grew (although total dollars decreased) from ~350 deals (\$254 billion) in 2019 to 384 deals (\$190.9 billion) in 2020. Deal activity so far in 2021 has been relatively muted, but strong innovation and competition could trigger a recovery in M&A activity.

One method to quantify biotechnology innovation is through the <u>FDA</u>'s novel drug approval list. The FDA <u>defines</u> novel drugs as "innovative products that serve previously unmet medical needs or otherwise significantly help to advance patient treatments" where the active ingredient has not previously been approved in the United States. In 2020, the FDA's Center of Drug Evaluation and Research (CDER) <u>approved</u> 53 novel drugs—above the average rate of 40 novel drugs per year since 2011-2019. So far novel drug approvals in 2021 are about in line with last year with 26 drugs <u>approved</u> year-to-date as of June 7. Examples of novel drugs that have recently gained publicity are remdesivir (approved October 22, 2020 to treat COVID-19) and aducanumab (approved June, 7, 2021 to treat Alzheimer's disease).

Given the volatility and uncertainty in the sector, biotechnology is a difficult space for individual stock picking and many investors instead choose to follow an index strategy. Broader healthcare indexes, however, tend to lack concentrated biotechnology exposure. The <u>S&P 500 Health Care Index</u> (S5HLTH) does not contain any PMBI or PHIX constituents, although it does contain larger biotechnology companies (all of its top 10 constituents have market caps over \$100 billion). PMBI focuses on small to mid-cap stocks with market caps ranging from \$200 million to \$5 billion, while PHIX focuses on those with relatively higher market caps from \$1 billion to \$50 billion. The screening strategy behind PMBI and PHIX has helped achieve higher total return than S5HLTH over the past five years (115.6% for PMBI and 172.2% for PHIX compared to 91.0% for S5HLTH), which further validates its benefits over a broad-based sector strategy for those investors seeking a thematic growth opportunity.







Source: Bloomberg, Alerian and S-Network Global Indexes as of 6/11/2021

| | | Total-Return Performance | | | | |
|--|---------|--------------------------|--------|--------|---------|---------|
| Index | Ticker | 30 Days | YTD | 1-Year | 3-Year | 5-Year |
| Healthcare | | | | | | |
| S-Network Healthcare Technology Index | HLTHX | 9.75% | -1.81% | 53.16% | 130.36% | 232.33% |
| S-Network Medical Breakthroughs Index | PMBI | 11.61% | -2.64% | 26.46% | 33.78% | 115.62% |
| S-Network Healthcare Innovation Index | PHIX | 11.22% | -1.81% | 16.31% | 52.11% | 172.16% |
| | | | | | | |
| Technology | | | | | | |
| O'Shares Global Internet Giants Index | OGIGX | 10.39% | 0.11% | 59.32% | 119.14% | 340.85% |
| S-Network North American Disruptor Index | SNNADX | 13.40% | 15.81% | 67.04% | 78.58% | N/A |
| S-Network US Disruptor Index | SNUSDX | 16.59% | 18.35% | 81.22% | 93.48% | 245.41% |
| S-Network Tech Target Index | SNTECH | 13.08% | 15.06% | 70.76% | 60.97% | 183.22% |
| | | | | | | |
| Water | | | | | | |
| S-Network Global Water Index | JGI | 6.63% | 13.29% | 39.62% | 51.44% | 85.39% |
| S-Network Global Water Works Index | JWW | 4.80% | 10.05% | 21.92% | 52.60% | 75.59% |
| S-Network Global Water Technology Index | JWT | 8.53% | 16.61% | 58.72% | 45.83% | 89.23% |
| | | | | | | |
| Smart Climate Risk | | | | | | |
| S-Network Smart Climate Risk 50 Index | SNSC50 | 3.53% | 12.54% | 38.01% | 54.25% | 128.43% |
| S-Network Smart Climate Risk 250 Index | SNSC250 | 3.28% | 13.83% | 40.80% | 56.70% | 128.54% |
| Other: | | | | | | |
| Other | STREAM | 10.94% | 12.11% | 71.55% | 99.16% | N/A |
| S-Network Streaming & Gaming Index S-Network Infrastructure Builders Index | | | | | | , |
| | EIBI | -1.96% | 14.75% | 49.64% | 28.39% | 74.36% |
| S-Network Space Index | SPACE | 7.39% | 21.09% | 59.11% | 22.14% | 56.13% |
| S-Network MicroSectors Gold Miners Index | MINERS | 4.49% | 3.97% | 18.58% | 70.16% | N/A |

Source: S-Network Global Indexes. All performance data as of June 11, 2021.



Related Research:

Biotechnology: Capturing Innovation and Potential M&A Upside

Capturing Biotech Innovators and M&A Targets

Investing in Space: Growth Beyond this World

Riding the ESG Wave by Investing in Water

How Is Digitization Impacting Businesses and Creating Opportunities for Investors?

Underlying Index | Associated Product/Direct-Indexing Platform Availability

Healthcare

S-Network Medical Breakthroughs Index (PMBI) | ALPS Medical Breakthroughs ETF (SBIO)

S-Network Healthcare Innovation Index (PHIX) | SmartTrust Healthcare Innovations Trust; Available on the C8 platform and the SMArtX platform

Technology

O'Shares Global Internet Giants Index (OGIGX) | O'Shares Global Internet Giants ETF (OGIG)

S-Network North American Disruptor Index (SNNADX) | SmartTrust Technology Revolution Trust - Includes 30 stocks from SNNADX

S-Network US Disruptor Index (SNUSDX) | Available on the SMArtX platform

S-Network Tech Target Index (SNTECH) | Available on the SMArtX Platform

Water

S-Network Global Water Index (JGI) | Invesco Global Water Portfolio – Includes 25 stocks from JGI; Available on the C8 platform

Smart Climate Risk

S-Network Smart Climate Risk 50 Index (SNSC50) | Available on the C8 platform and the SMArtX platform S-Network Smart Climate Risk 250 Index (SNSC250) | Available on the C8 platform

Other

S-Network Infrastructure Builders Index (EIBI) | Available on the C8 platform

S-Network Space Index (SPACE) | Procure Space ETF (UFO)

S-Network MicroSectors Gold Miners Index (MINERS) | MicroSectors Gold Miners 3x Leveraged ETN (GDXU), MicroSectors Gold Miners -3x Inverse Leveraged ETN (GDXD)

About Alerian and S-Network Global Indexes

Alerian is a leading independent index provider focused on building innovative, index-based investment strategies. Alerian acquired S-Network Global Indexes in 2020, expanding the firm's index offerings and services to partners. Combined, the firm serves the global investment community through indexing, benchmarking, and calculation services. Built on a foundation of data rigor and specialty research, Alerian and S-Network Global Indexes offer a comprehensive family of energy, income, and thematic indexes. Today, the firm has over \$23 billion in total assets benchmarked to its indexes and over 200 customers world-wide.



Disclaimers

This Document Is Impersonal and Not a Solicitation. In jurisdictions where Alerian, S-Network Global Indexes, or their affiliates do not have the necessary licenses, this document does not constitute an offering of any security, product, or service. Alerian and S-Network Global Indexes receive compensation in connection with licensing its indices to third parties. All information provided by Alerian and S-Network Global Indexes in this document is impersonal and not customized to the specific needs of any entity, person, or group of persons. Alerian, S-Network Global Indexes, and their affiliates do not endorse, manage, promote, sell, or sponsor any investment fund or other vehicle that is offered by third parties and that seeks to provide an investment return linked to or based on the returns of any Alerian or S-Network Global Indexes index.

No Advisory Relationship. Alerian and S-Network Global Indexes are not investment advisors, and Alerian, S-Network Global Indexes, and their affiliates make no representation regarding the advisability of investing in any investment fund or other vehicle. This document should not be construed to provide advice of any kind, including, but not limited to, tax and legal.

You Must Make Your Own Investment Decision. It is not possible to invest directly in an index. Index performance does not reflect the deduction of any fees or expenses. Past performance is not a guarantee of future returns. You should not make a decision to invest in any investment fund or other vehicle based on the statements set forth in this document, and are advised to make an investment in any investment fund or other vehicle only after carefully evaluating the risks associated with investment in the investment fund, as detailed in the offering memorandum or similar document prepared by or on behalf of the issuer. This document does not contain, and does not purport to contain, the level of detail necessary to give sufficient basis to an investment decision. The addition, removal, or inclusion of a security in any Alerian or S-Network Global Indexes index is not a recommendation to buy, sell, or hold that security, nor is it investment advice.

No Warranties. The accuracy and/or completeness of any Alerian or S-Network Global Indexes index, any data included therein, or any data from which it is based is not guaranteed by Alerian or S-Network Global Indexes, and it shall have no liability for any errors, omissions, or interruptions therein. Alerian and and S-Network Global Indexes make no warranties, express or implied, as to results to be obtained from use of information provided by Alerian and S-Network Global Indexes and used in this service, and Alerian and S-Network Global Indexes expressly disclaim all warranties of suitability with respect thereto.

Limitation of Liability. While Alerian and S-Network Global Indexes believe that the information provided in this document is reliable, Alerian and S-Network Global Indexes shall not be liable for any claims or losses of any nature in connection with the use of the information in this document, including but not limited to, lost profits or punitive or consequential damages, even if Alerian and S-Network Global Indexes have been advised of the possibility of same.

Research May Not Be Current. This document has been prepared solely for informational purposes based on information generally available to the public from sources believed to be reliable. Alerian and S-Network Global Indexes make no representation as to the accuracy or completeness of this document, the content of which may change without notice. Alerian and S-Network Global Indexes expressly disclaim any obligation to update the contents of this document to reflect developments in the energy Master Limited Partnership sector. The methodology involves rebalancings and maintenance of indices that are made periodically throughout the year and may not, therefore, reflect real-time information.

Linked Products. Alerian and S-Network Global Indexes licenses its indexes to third parties for the creation of investment funds or other vehicles. Alerian and S-Network Global Indexes are not responsible for the information on these websites or for anything that they provide.

Policies and Procedures. Analytic services and products provided by Alerian and S-Network Global Indexes are the result of separate activities designed to preserve the independence and objectivity of each analytic process. Alerian and S-Network Global Indexes have established policies and procedures to maintain the confidentiality of material non-public information received during each analytic process. Alerian, S-Network Global Indexes, and their affiliates provide a wide range of services to, or relating to, many organizations, and may receive fees or other economic benefits from these organizations.

Copyright. No Unauthorized Redistribution. Alerian and S-Network Global Indexes © 2021. All rights reserved. This document, in whole or in part, may not be redistributed, reproduced, and/or photocopied without prior written permission.

Alerian

alerian.com info@alerian.com | 972.957.7700 3625 N. Hall St., Suite 1200, Dallas, TX 75219

S-Network Global Indexes

snetworkglobalindexes.com info@snetworkinc.com | 646.467.7928 267 Fifth Avenue, Suite 508, New York, NY, 10016